UPK1B and invasive carcinoma: The marked decrease of both prevalence and intensity of Upk1a and Upk1b immunostaining from non-invasive (pTa) to muscle-invasive carcinomas (pT2-4) reflects a striking loss of Upk expression during bladder cancer progression.